Parathyroid hormone decreases endothelial osteoprotegerin secretion: Role of protein kinase a and C

American Journal of Physiology - Renal Physiology

Volumn 296, Issue 1, 2009, Pages

  Rashid, Gloria ^a   Plotkin, Eleanora ^a,b   Klein, Osnat ^a,b   Green, Janice ^a   Bernheim, Jacques ^a,b   Benchetrit, Sydney ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Endothelial cells

Indexed keywords

CALPHOSTIN C; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ENZYME ACTIVATOR; MESSENGER RNA; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROTEIN KINASE A ACTIVATOR; PROTEIN KINASE C; PROTEIN KINASE C ACTIVATOR; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD VESSEL CALCIFICATION; CONTROLLED STUDY; ENDOTHELIUM; ENDOTHELIUM CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN SECRETION;

EID: 58849161832     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00622.2007     Document Type: Article

References (47)

1. Avbersek-Luznik I, Malesic I, Rus I, Marc J. Increased levels of osteoprotegerin in hemodialysis patients. Clin Chem Lab Med 40: 1019-1023, 2002.
2. Bro S, Olgaard K. Effect of excess PTH on nonclassical target organs. Am J Kidney Dis 30: 606-620, 1997.
3. Brown EM. Homeostatic mechanisms regulating extracellular and intracellular calcium metabolism. In: The Parathyroids, edited by Bilezikian JP, Levine MA, and Marcus R. New York: Raven, 1994.
4. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab 86 :631-637, 2001.
5. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin- deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12: 1260-1268, 1998.
6. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W, Osdoby P. Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276: 20659-20672, 2001.
7. de Souza NJ, Dohadwalla AN, Reden J. Forskolin: a labdane diterpenoid with antihypertensive, positive inotropic, platelet aggregation inhibitory, and adenylate cyclase activating properties. Med Res Rev 3: 201-219, 1983.
8. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ, Tordoir JH, Spronk HM, Vermeer C, Daemen MJ. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 21:1998-2003, 2001.
9. Fahrleitner A, Prenner G, Leb G, Tscheliessnigg KH, Piswanger-Sölkner C, Obermayer-Pietsch B, Portugaller HR, Berghold A, Dobnig H. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone 32: 96-106, 2003.
10. Filvaroff E, Derynck R. Bone remodelling: a signalling system for osteoclast regulation. Curr Biol 8: R679-R682, 1998.
11. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32: S112-S119, 1998.
12. Fu Q, Jilka RL, Manolagas SC, O'Brien CA. Parathyroid hormone stimulates receptor activator of NFkB ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J Biol Chem 277: 48868-48875, 2002.
13. Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Domenig C, Zsontsich T, Klaushofer K, Delling G, Oberbauer R. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. Am J Kidney Dis 39: 580-586, 2002.
14. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15: 2-12, 2000.
15. Jono S, Ikari Y, Shioi A, Mori K, Miki T, Hara K, Nishizawa Y. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation 106: 1192-1194, 2002.
16. Kiechl S, Schett G, Wenning G, Redlich K, Oberhollenzer M, Mayr A, Santer P, Smolen J, Poewe W, Willeit J. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation 109: 2175-2180, 2004.
17. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 159: 548-553, 1989.
18. Liu WS, Heckman CA. The sevenfold way of PKC regulation. Cell Signal 10: 529-542, 1998.
19. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003.
20. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA, Giachelli CM. Osteoprotegerin is an alpha-v beta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem 275: 20959-20962, 2000.
21. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med 21: 192: 463-474, 2000.
22. Moe SM, O'Neill KD, Reslerova M, Fineberg N, Persohn S, Meyer CA. Natural history of vascular calcification in dialysis and transplant patients. Nephrol Dial Transplant 19: 2387-2393, 2004.
23. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 117: 411-420, 2008.
24. Neves KR, Graciolli FG, dos Reis LM, Graciolli RG, Neves CL, Magalhães AO, Custódio MR, Batista DG, Jorgetti V, Moysés RM. Vascular calcification: contribution of parathyroid hormone in renal failure. Kidney Int 71: 1262-1270, 2007.
25. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H. The progression of vascular calcification and serum osteoprotegerin levels in patients on long term hemodialysis. Am J Kidney Dis 42: 303-309, 2003.
26. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol 21: 1610-1616, 2001.
27. Pritzker LB, Scatena M, Giachelli CM. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15: 2834-2841, 2004.
28. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. Am J Physiol Renal Physiol 292: F1215-F1218, 2007.
29. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates the endothelial nitric oxide synthase through protein kinase A and C pathways. Nephrol Dial Transplant 22: 2831-2837, 2007.
30. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 56: 383-392, 1999.
31. Rothermel JD, Stec WJ, Baraniak J, Jastorff B, Botelho LH. Inhibition of glycogenolysis in isolated rat hepatocytes by the Rp diastereomer of adenosine cyclic 3′,5′-phosphorothioate. J Biol Chem 258: 12125-12128, 1983.
32. Sasaki N, Kusano E, Ando Y, Nemoto J, Iimura O, Ito C, Takeda S, Yano K, Tsuda E, Asano Y. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis. Bone 30: 853-858, 2002.
33. Sattler AM, Schoppet M, Schaefer JR, Hofbauer LC. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 74: 103-106, 2004.
34. Schluter KD. PTH and PTHrP: similar structures but different functions. News Physiol Sci 14: 243-249, 1999.
35. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22: 549-553, 2002.
36. Schoppet M, Sattler AM, Schaefer JR, Herzum M, Maisch B, Hofbauer LC. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab 88: 1024-1028, 2003.
37. Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G, Mall G, Amann K. Morphology of coronary atherosclerotic lesions in patients with end-stage renal failure. Nephrol Dial Transplant 15: 218-223, 2000.
38. Secchiero P, Corallini F, Pandolfi A, Consoli A, Candido R, Fabris B, Celeghini C, Capitani S, Zauli G. An increased osteoprotegerin serum release characterizes the early onset of diabetes mellitus and may contribute to endothelial cell dysfunction. Am J Pathol 169: 2236-2244, 2006.
39. Simonet WS, Lacey DL, Dunstan CR. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
40. Stenvinkel P, Alvestrand A. Inflammation in end stage renal disease: sources, consequences and therapy. Semin Dial 15: 329-337, 2002.
41. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20: 345-357, 1999.
42. Takami M, Takahashi N, Udagawa N, Miyaura C, Suda K, Woo JT, Martin TJ, Nagai K, Suda T. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kB ligand and osteoprotegerin in osteoblasts. Endocrinology 141: 4711-4719, 2002.
43. Ueland T, Jemtland R, Godang K, Kjekshus J, Hognestad A, Omland T, Squire IB, Gullestad L, Bollerslev J, Dickstein K, Aukrust P. Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. J Am Coll Cardiol 44: 1970-1976, 2004.
44. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 65: 715-724, 1999.
45. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, Kanno T, Murakami A, Tsuda E, Morinaga T, Higashio K. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139: 1329-1337, 1998.
46. Zannettino AC, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM, Haynes DR. Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol 204: 714-723, 2005.
47. Zauli G, Corallini F, Bossi F, Fischetti F, Durigutto P, Celeghini C, Tedesco F, Secchiero P. Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood 110: 536-543, 2007.